Therapeutic effects of mesenchymal stem cells for patients with chronic liver diseases

Systematic review and meta-analysis

Gaeun Kim, Young Woo Eom, Soonkoo Baik, Yeonghee Shin, Yoo Li Lim, Moonyoung Kim, Sang Ok Kwon, Sei Jin Chang

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Based on their ability to differentiate into multiple cell types including hepatocytes, the transplantation of mesenchymal stem cells (MSCs) has been suggested as an effective therapy for chronic liver diseases. The aim of this study was to evaluate the safety, efficacy and therapeutic effects of MSCs in patients with chronic liver disease through a literature-based examination. We performed a systematic review (SR) and meta-analysis (MA) of the literature using the Ovid-MEDLINE, EMBASE and Cochrane Library databases (up to November 2014) to identify clinical studies in which patients with liver diseases were treated with MSC therapy. Of the 568 studies identified by the initial literature search, we analyzed 14 studies and 448 patients based on our selection criteria. None of the studies reported the occurrence of statistically significant adverse events, side effects or complications. The majority of the analyzed studies showed improvements in liver function, ascites and encephalopathy. In particular, an MA showed that MSC therapy improved the total bilirubin level, the serum albumin level and the Model for End-stage Liver Disease (MELD) score after MSC treatment. Based on these results, MSC transplantation is considered to be safe for the treatment of chronic liver disease. However, although MSCs are potential therapeutic agents that may improve liver function, in order to obtain meaningful insights into their clinical efficacy, further robust clinical studies must be conducted to evaluate the clinical outcomes, such as histological improvement, increased survival and reduced liver-related complications, in patients with chronic liver disease.

Original languageEnglish
Pages (from-to)1405-1415
Number of pages11
JournalJournal of Korean medical science
Volume30
Issue number10
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Therapeutic Uses
Mesenchymal Stromal Cells
Meta-Analysis
Liver Diseases
Chronic Disease
Mesenchymal Stem Cell Transplantation
Cell- and Tissue-Based Therapy
Liver
End Stage Liver Disease
Brain Diseases
Therapeutics
Bilirubin
Ascites
MEDLINE
Serum Albumin
Patient Selection
Libraries
Hepatocytes
Databases
Safety

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kim, Gaeun ; Eom, Young Woo ; Baik, Soonkoo ; Shin, Yeonghee ; Lim, Yoo Li ; Kim, Moonyoung ; Kwon, Sang Ok ; Chang, Sei Jin. / Therapeutic effects of mesenchymal stem cells for patients with chronic liver diseases : Systematic review and meta-analysis. In: Journal of Korean medical science. 2015 ; Vol. 30, No. 10. pp. 1405-1415.
@article{2458a6ec520a4abea4f45c1b438831f1,
title = "Therapeutic effects of mesenchymal stem cells for patients with chronic liver diseases: Systematic review and meta-analysis",
abstract = "Based on their ability to differentiate into multiple cell types including hepatocytes, the transplantation of mesenchymal stem cells (MSCs) has been suggested as an effective therapy for chronic liver diseases. The aim of this study was to evaluate the safety, efficacy and therapeutic effects of MSCs in patients with chronic liver disease through a literature-based examination. We performed a systematic review (SR) and meta-analysis (MA) of the literature using the Ovid-MEDLINE, EMBASE and Cochrane Library databases (up to November 2014) to identify clinical studies in which patients with liver diseases were treated with MSC therapy. Of the 568 studies identified by the initial literature search, we analyzed 14 studies and 448 patients based on our selection criteria. None of the studies reported the occurrence of statistically significant adverse events, side effects or complications. The majority of the analyzed studies showed improvements in liver function, ascites and encephalopathy. In particular, an MA showed that MSC therapy improved the total bilirubin level, the serum albumin level and the Model for End-stage Liver Disease (MELD) score after MSC treatment. Based on these results, MSC transplantation is considered to be safe for the treatment of chronic liver disease. However, although MSCs are potential therapeutic agents that may improve liver function, in order to obtain meaningful insights into their clinical efficacy, further robust clinical studies must be conducted to evaluate the clinical outcomes, such as histological improvement, increased survival and reduced liver-related complications, in patients with chronic liver disease.",
author = "Gaeun Kim and Eom, {Young Woo} and Soonkoo Baik and Yeonghee Shin and Lim, {Yoo Li} and Moonyoung Kim and Kwon, {Sang Ok} and Chang, {Sei Jin}",
year = "2015",
month = "1",
day = "1",
doi = "10.3346/jkms.2015.30.10.1405",
language = "English",
volume = "30",
pages = "1405--1415",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "10",

}

Therapeutic effects of mesenchymal stem cells for patients with chronic liver diseases : Systematic review and meta-analysis. / Kim, Gaeun; Eom, Young Woo; Baik, Soonkoo; Shin, Yeonghee; Lim, Yoo Li; Kim, Moonyoung; Kwon, Sang Ok; Chang, Sei Jin.

In: Journal of Korean medical science, Vol. 30, No. 10, 01.01.2015, p. 1405-1415.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapeutic effects of mesenchymal stem cells for patients with chronic liver diseases

T2 - Systematic review and meta-analysis

AU - Kim, Gaeun

AU - Eom, Young Woo

AU - Baik, Soonkoo

AU - Shin, Yeonghee

AU - Lim, Yoo Li

AU - Kim, Moonyoung

AU - Kwon, Sang Ok

AU - Chang, Sei Jin

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Based on their ability to differentiate into multiple cell types including hepatocytes, the transplantation of mesenchymal stem cells (MSCs) has been suggested as an effective therapy for chronic liver diseases. The aim of this study was to evaluate the safety, efficacy and therapeutic effects of MSCs in patients with chronic liver disease through a literature-based examination. We performed a systematic review (SR) and meta-analysis (MA) of the literature using the Ovid-MEDLINE, EMBASE and Cochrane Library databases (up to November 2014) to identify clinical studies in which patients with liver diseases were treated with MSC therapy. Of the 568 studies identified by the initial literature search, we analyzed 14 studies and 448 patients based on our selection criteria. None of the studies reported the occurrence of statistically significant adverse events, side effects or complications. The majority of the analyzed studies showed improvements in liver function, ascites and encephalopathy. In particular, an MA showed that MSC therapy improved the total bilirubin level, the serum albumin level and the Model for End-stage Liver Disease (MELD) score after MSC treatment. Based on these results, MSC transplantation is considered to be safe for the treatment of chronic liver disease. However, although MSCs are potential therapeutic agents that may improve liver function, in order to obtain meaningful insights into their clinical efficacy, further robust clinical studies must be conducted to evaluate the clinical outcomes, such as histological improvement, increased survival and reduced liver-related complications, in patients with chronic liver disease.

AB - Based on their ability to differentiate into multiple cell types including hepatocytes, the transplantation of mesenchymal stem cells (MSCs) has been suggested as an effective therapy for chronic liver diseases. The aim of this study was to evaluate the safety, efficacy and therapeutic effects of MSCs in patients with chronic liver disease through a literature-based examination. We performed a systematic review (SR) and meta-analysis (MA) of the literature using the Ovid-MEDLINE, EMBASE and Cochrane Library databases (up to November 2014) to identify clinical studies in which patients with liver diseases were treated with MSC therapy. Of the 568 studies identified by the initial literature search, we analyzed 14 studies and 448 patients based on our selection criteria. None of the studies reported the occurrence of statistically significant adverse events, side effects or complications. The majority of the analyzed studies showed improvements in liver function, ascites and encephalopathy. In particular, an MA showed that MSC therapy improved the total bilirubin level, the serum albumin level and the Model for End-stage Liver Disease (MELD) score after MSC treatment. Based on these results, MSC transplantation is considered to be safe for the treatment of chronic liver disease. However, although MSCs are potential therapeutic agents that may improve liver function, in order to obtain meaningful insights into their clinical efficacy, further robust clinical studies must be conducted to evaluate the clinical outcomes, such as histological improvement, increased survival and reduced liver-related complications, in patients with chronic liver disease.

UR - http://www.scopus.com/inward/record.url?scp=84945914046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945914046&partnerID=8YFLogxK

U2 - 10.3346/jkms.2015.30.10.1405

DO - 10.3346/jkms.2015.30.10.1405

M3 - Article

VL - 30

SP - 1405

EP - 1415

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 10

ER -